Founded in 2019, Great Bay Bio is a biotech company that drives drug development using cutting-edge technologies such as AI, big data mining, and automation.

Leveraging our proprietary technology platforms, Great Bay Bio has established a comprehensive product pipeline in the fields of metabolic diseases (obesity), oncology, and autoimmune disorders. By integrating intelligent algorithms, site-specific integration platforms, and high-throughput screening technologies, we have significantly shortened the PCC candidate development timeline from the traditional 1.5–2 years to less than 8 months—achieving a leap from molecular discovery to the preclinical stage and redefining the speed and quality of drug discovery through technology.

We are currently seeking out-licensing partners for our innovative pipeline assets.

https://www.greatbay-bio.com/